Anesthesia Pharmacology: Autonomic Pharmacology Adrenergic Drugs
Drugs that affect (or mimic) adrenergic function (Mechanisms)46:
I. Interference with transmitter synthesis: α-methyltyrosine, which inhibits tyrosine hydroxylase (tyrosine 3-monooxygenase), leading to depletion of the endogenous neurotransmitter, norepinephrine (NE)
|
|
II. Drug is transformed using the same pathway as the endogenous precursors46
Methyldopa (Aldomet) , L-α-methyl-3,4 diphydroxyphenylalanine, is transformed in a reaction catalyzed by dopamine-β-hydroxylase to α-methyl-norepinephrine which acts in the CNS as an α2-agonist.
The result of central α2-receptor activation is a reduction of sympathetic outflow.
|
|
III. Inhibition of nerve terminal membrane transport
By blockade of this transport system, drugs such as cocaine and tricyclic antidepressant drugs, e.g. imipramine (Tofranil) increase synaptic cleft [NE] which increases the likelihood of adrenergic receptor activation.
|
|
Cocaine |
Imipramine (Tofranil) |
Norepinephrine Transporter (NET) |
Transporter specificity: dopamine > norepinephrine > epinephrine |
|
NET inhibitors: desipramine (tricyclic antidepressant drug); cocaine |
Dopamine Transporter (DAT) |
Transporter specificity: dopamine >>> norepinephrine > epinephrine |
|
DAT inhibitors: cocaine |
The norepinephrine transporter (NET) in addition to be inhibited by tricyclic antidepressants and cocaine is also Na+-dependent.
The transporter has a higher affinity for norepinephrine compared to epinephrine; whereas, isoproterenol is not transported.
Other specific neurotransmitter transport systems have been described, including examples for dopamine, serotonin, and amino acids.
Such transporters exhibit a common transmembrane structure consisting of 12-helices.
Displacement of nerve terminal norepinephrine by ephedrine and tyramine (sympathomimetic agents) also depends on NET.
When, for example, ephedrine is transported across the neuronal membrane by this transporter and is released into the intracellular cytoplasm, the open transporter carrier sites become available at the inner membrane surface.
These open sites then can transport norepinephrine outward in a process described as "facilitated exchange diffusion."
Ephedrine and tyramine also compete for norepinephrine uptake into vesicles and as a result tend to mobilize these neurotransmitter stores also.
As noted earlier, extraneuronal transporters are also present.
One example is ENT a.k.a. uptake-2 and OCT3.
ENT is not Na+-dependent and transports organic cations.
Other organic cation transporters include OCT1 and OCT2.
These transporters not only act on catecholamines but also other organic acids such as serotonin, guanidine, creatinine, and histamine.
The NET transporter plays an important role in termination of norepinephrine and epinephrine action.
Reuptake of these catecholamines by NET is a principal mechanism for limiting extended catecholamine-mediated adrenergic receptor activation.
Extraneuronal uptake of catecholamines, following diffusion away from the synaptic cleft, also limits catecholamine duration of action.
Metabolic transformation of the catecholamines by MAO (monoamine oxidase) and COMT (catechol-O-methyl transferase) is a third factor in termination of catecholamine actions.
IV. Vesicular transport system inhibition46
Blockade of this transport system (VMAT, vesicular monoamine transporter) results in depletion of norepinephrine from adrenergic nerve endings.
Inability of NE to be transported into synaptic vesicles exposes the neurotransmitter to enzymatic breakdown, catalyzed by mitochondrial monoamine oxidase (MAO).
Reserpine is probably the best-known agent exhibiting vesicular transport blockade.
|
|
|
V. Drugs that displace neurotransmitters from nerve terminals:46
Amphetamine and tyramine are examples of drugs in this category.
The result of their action is "adrenomimetic."
|
|
Amphetamine |
Tyramine |
VI. Bretylium and guanadrel (Hyorel) prevent adrenergic neurotransmitter release.
|
|
|
|
Bretylium |
Guanadrel (Hyorel) |
|
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information. Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals. |